ESSA Pharma  logo
ESSA Pharma EPIX

Quarterly report 2025-Q2
added 08-13-2025

report update icon

ESSA Pharma Financial Ratios 2011-2026 | EPIX

Annual Financial Ratios ESSA Pharma

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-2.6 -8.7 -4.0 -8.4 -5.8 -3.8 -1.2 -1.7 -4.5 -12.9 - - - -

EPS

-0.6 -0.6 -0.8 -1.0 -1.0 -1.5 - - - - - - - -

EV (Enterprise Value)

-26.7 M 201 M 86.2 M 174 M 81.9 M -7.67 M 5.96 M 18.2 M 70.1 M 113 M 2.23 M - - -

EBITDA per Share

- - - - -1.02 -1.44 -2.36 -7.44 -13.9 -10 - - - -

EV/EBITDA

- -3.5 0.8 -0.5 -1.1 -2.7 -11.8 - - - -

PEG

0.15 -0.36 -0.07 -0.08 -0.02 1.02 0.04 - - - -

P/B

0.6 1.6 0.8 1.6 1.7 0.8 1.5 -1.8 -110.2 24.9 - - - -

P/CF

-3.2 -11.7 -5.0 -12.1 -8.1 -3.3 -1.4 -0.5 -3.9 -8.8 - - - -

ROE %

-22.91 -18.25 -21.01 -18.97 -29.59 -21.23 -127.07 105.00 2447.54 -193.46 - - - -

ROA %

-22.28 -17.83 -20.71 -18.57 -29.10 -19.06 -72.61 -84.24 -126.31 -114.32 - - - -

ROCE %

- - - - -29.63 -24.74 -85.24 -676.89 3484.04 -208.49 - - - -

Current Ratio

36.5 42.7 71.0 47.6 66.7 9.7 4.7 1.3 0.9 2.3 - - - -

All numbers in USD currency

Quarterly Financial Ratios ESSA Pharma

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.09 -0.14 -0.19 - -0.16 -0.2 -0.14 - -0.17 -0.16 -0.15 - -0.2 -0.25 -0.21 - -0.56 -0.36 -0.2 -0.91 -0.24 -0.2 -0.22 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-22.09 -24.03 -25.15 -16.59 -21.45 -20.69 -18.47 -13.54 -18.68 -18.97 -20.53 -16.07 -20.45 -19.69 -20.53 -20.11 -28.92 -33.34 -35.24 -36.50 -27.69 -18.87 -10.06 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-21.56 -23.39 -24.38 -16.10 -20.85 -20.15 -18.08 -13.29 -13.29 -14.48 -15.97 -16.64 -15.00 -19.30 -19.89 -19.41 -27.52 -31.32 -32.88 -24.31 -16.21 -8.10 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

69.1 61.8 31.7 36.5 34.9 31.1 38.0 42.7 45.1 73.2 55.3 71.0 - 46.9 48.5 47.6 53.2 47.6 36.7 60.5 60.5 60.5 - 9.8 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company ESSA Pharma , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
argenx SE argenx SE
ARGX
$ 834.06 0.94 % $ 25 B niderlandNiderland
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 234.24 -0.3 % $ 5 B danmarkDanmark
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.81 1.31 % $ 4.42 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 4.66 1.42 % $ 393 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 167.61 -4.09 % $ 8.34 B usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.33 0.79 % $ 8.01 B australiaAustralia
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
BioVie BioVie
BIVI
$ 1.25 0.4 % $ 1.85 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 63.02 0.15 % $ 12 B usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
$ 0.79 4.29 % $ 108 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 12.71 10.81 % $ 837 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Capricor Therapeutics Capricor Therapeutics
CAPR
$ 27.89 0.07 % $ 747 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 110.88 0.86 % $ 27.2 B germanyGermany
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.72 2.08 % $ 4.55 B usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Certara Certara
CERT
$ 6.67 2.77 % $ 1.07 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.32 1.25 % $ 1.5 B britainBritain
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.85 6.65 % $ 472 M britainBritain